本帖最后由 老马 于 2012-1-13 21:20 编辑 ! G, o- w9 ~' `
$ K6 X- e* b$ }8 }
爱必妥和阿瓦斯丁的比较* ?/ U: w% W1 L V
# G4 q! w3 l F1 z' w$ |
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/9 a! ]2 \: A1 y) `/ o7 V7 _! X, W* |
) a/ T) H0 H4 U6 m5 Y q+ K
# P/ I4 M3 S0 s5 ~0 T0 ^( Hhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
3 M# @6 t% S, z' P==================================================: j3 l. {; Z% l1 `) a
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)& s( }7 @" i0 M+ D
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
' y9 J8 V8 X- {/ W6 kResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ d# A3 S! _% [9 I" s% S
|